206 related articles for article (PubMed ID: 15457893)
1. Bad tiered formulary designs yield poor outcomes, high cost.
Sipkoff M
Manag Care; 2004 Aug; 13(8):27, 31-2, 34-5. PubMed ID: 15457893
[No Abstract] [Full Text] [Related]
2. Consumer attitudes and factors related to prescription switching decisions in multitier copayment drug benefit plans.
Ganther-Urmie JM; Nair KV; Valuck R; McCollum M; Lewis SJ; Turpin RS
Am J Manag Care; 2004 Mar; 10(3):201-8. PubMed ID: 15032257
[TBL] [Abstract][Full Text] [Related]
3. Do drug formulary policies reflect evidence of value?
Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
[TBL] [Abstract][Full Text] [Related]
4. Pharmaceuticals issue brief: managed care drug formularies: year end report-2003.
MacEachern L
Issue Brief Health Policy Track Serv; 2003 Dec; ():1-8. PubMed ID: 14969259
[TBL] [Abstract][Full Text] [Related]
5. Promise and perils for patients and physicians.
Kravitz RL; Chang S
N Engl J Med; 2005 Dec; 353(26):2735-9. PubMed ID: 16382057
[No Abstract] [Full Text] [Related]
6. Influencing drug formulary and contract performance.
Navarro RP
Manag Care Interface; 1999 Apr; 12(4):89-91, 96. PubMed ID: 10387398
[No Abstract] [Full Text] [Related]
7. Injectable drugs: the new frontier in pharmacy management.
Rodgers JR
Am J Manag Care; 2003 Jun; Suppl Decision Maker News():5-8. PubMed ID: 12866365
[No Abstract] [Full Text] [Related]
8. Forecasting the future.
Tecnologica; 1999 Dec; ():1, 3-6, 14-5. PubMed ID: 10848110
[No Abstract] [Full Text] [Related]
9. What you need to know about Medicare Part D.
Consum Rep; 2006 Feb; 71(2):34-6. PubMed ID: 16509047
[No Abstract] [Full Text] [Related]
10. Data watch. Is this the way to manage pharmacy costs?
Bus Health; 1997 Sep; 15(9):94. PubMed ID: 10173238
[No Abstract] [Full Text] [Related]
11. The effect of tiered-copay formularies on prescription drug use and spending.
Manag Care Interface; 2004 Apr; 17(4):68-9. PubMed ID: 15108762
[No Abstract] [Full Text] [Related]
12. Impact of formulary restrictions on patient safety.
Lazarus A
Physician Exec; 2005; 31(4):42-4. PubMed ID: 16285169
[No Abstract] [Full Text] [Related]
13. The pitfalls and potential of pharmacy risk.
Lawrence J
Manag Care; 1998 May; 7(5):45-6, 51-2. PubMed ID: 10180140
[No Abstract] [Full Text] [Related]
14. How effectively do managed care organizations influence prescribing and dispensing decisions?
Carroll NV
Am J Manag Care; 2002 Dec; 8(12):1041-54. PubMed ID: 12500881
[TBL] [Abstract][Full Text] [Related]
15. "Build it and they will come?".
Giaquinta D
Manag Care Interface; 2002 Oct; 15(10):44-5, 47. PubMed ID: 12391817
[No Abstract] [Full Text] [Related]
16. Pharmaceutical formularies: the right formula for cost and utilization?
Austin B
Find Brief; 2004 Aug; 7(5):1-3. PubMed ID: 15298009
[No Abstract] [Full Text] [Related]
17. Use of health-related quality of life information in managed care formulary decision-making.
Wu WK; Sause RB; Zacker C
Res Social Adm Pharm; 2005 Dec; 1(4):579-98. PubMed ID: 17138497
[TBL] [Abstract][Full Text] [Related]
18. Impact of formularies on clinical innovation.
Goodwin FK
J Clin Psychiatry; 2003; 64 Suppl 17():11-4. PubMed ID: 14680421
[TBL] [Abstract][Full Text] [Related]
19. Pharmaceutical management strategies of industrialized countries.
Brier KL
Formulary; 1995 Oct; 30(10):606-10, 614. PubMed ID: 10151724
[TBL] [Abstract][Full Text] [Related]
20. Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results.
Falit BP
Seton Hall Law Rev; 2007; 37(4):969-1049. PubMed ID: 18363220
[No Abstract] [Full Text] [Related]
[Next] [New Search]
